Back to results
US 7,138,274 B2Granted
Advanced oral poliovirus vaccine (Adv-OPV) deprived of the possibility of vaccine associated paralytic poliomyelities (VAPP)
AssigneeCreagene Inc.
InventorsYong-Soo Bae, Sang-Gu Lee, Hye-Rhan Jeong, Dong-Sung Lee, Ki-Tae Kim, Dae-You Kim
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel recombinant Sabin type 1 poliovirus vector for the immunogenicity of neutralizing antibody against polioviral infection, which comprises: (a) a genomic nucleotide sequence of a parent Sabin type 1 poliovirus; (b) a nucleotide sequence encoding an additional polioviral cleavage site; and (c) a nucleotide sequence of a conformational epitope encoding a VP1 neutralizing epitope of poliovirus type 2 or 3 and linked to the nucleotide sequence of (b).
Claims15
A recombinant Sabin type 1 poliovirus vector, which comprises:
- (a) a genomic nucleotide sequence of a Sabin type 1 poliovirus;
- (b) a nucleotide sequence encoding an additional polioviral cleavage site;
- and
- (c) a nucleotide sequence of less than 450 base pairs encoding a conformational epitope wherein said conformational epitope is selected from the group consisting of:
- a VP1 neutralizing epitope of poliovirus type 2 which is the sequence of amino acids 65–202 of SEQ ID NO:1, and a VP1 neutralizing epitope of poliovirus type 3 which is the sequence of amino acids 63–200 of SEQ ID NO:2.
2 more elements
Dependencies are inferred from the claim text.